comprehensive -WSS

comprehensive

author：comprehensive 2025-09-27 12:56:38 - browse：799

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Oak trusses raised to roof of fire

WSS

Leqembi, other new Alzheimer’s drugs require better biomarkers

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Racing yachts have close encounter with pod of orcas near Strait of Gibraltar

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

Dozens of Pride flags vandalized at Stonewall monument in NYC, 3rd time this month: Police

Medicare Advantage insurers pressure Biden for bigger payments

Wikipedia

comprehensive

entertainment

Apple is now the first public company to be valued at $3 trillion

Steward Health Care expansion into Malta flopped

Medical leaders decry Supreme Court decision on affirmative action

Biden launches a new push to limit health care costs

ChatGPT in medicine: STAT answers readers' burning questions

Elizabeth Holmes on track for early release from her 11

Activists slam private health insurers over coverage restrictions

Why ADHD is under

Malaria cases in Florida and Texas: Here’s what you need to know

It's time to get medical device identifiers over the finish line

hotspot

Mirador, a new biotech startup, launches with $400 million

Feng Zhang suggests Editas didn’t move quickly enough to find product targets

A new study sees potential in DNA sequencing of infants

Living with Fabry disease, a condition that causes chronic pain

Insurance companies sue energy corporation after it was blamed for helping start Colorado wildfire

What to know about OceanGate, the company behind the missing Titanic submersible

hotspot

knowledge

leisure time

knowledge